1. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies 
Amin M. Alousi, Jonathan E. Brammer, Rima M. Saliba, Borje Andersson, Uday Popat, Chitra Hosing, Roy Jones, Elizabeth J. Shpall, Issa Khouri, Muzaffar Qazilbash, Yago Nieto, Nina Shah, Sairah Ahmed, Betul Oran, Gheath Al Atrash, Stefan Ciurea, Partow Kebriaei, Julianne Chen, Gabriela Rondon, Richard E. Champlin 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 5, Pages (May 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Comparison of Acute GVHD II to IV (A), acute GVHD III/IV (B), nonrelapse mortality (C), relapse (D) and overall survival (E) in recipients of GVHD prophylaxis with Post-CY (dashed line) and tacrolimus/methotrexate (solid line) after RIC allogeneic transplantations from MRD and MUDs.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions